Stem Cell Transplant in India

Hematopoietic stem cell transplantation (HSCT) is performed at 50+ Indian centres for leukaemia, lymphoma, myeloma, aplastic anaemia, and thalassaemia. India is unique in offering haploidentical (50% HLA match) transplants at scale — expanding donor availability for all patients.

Check Your Eligibility — Free

Send your reports. Our specialists will review and confirm whether Stem Cell Transplant is right for your case.

📋 Get Free Assessment
Cost ComparisonIndiaUSA
Stem Cell Transplant$15,000–$35,000$150,000–$400,000
Savings60–80% less than USA

Conditions Treated with Stem Cell Transplant

  • Acute leukaemia (AML, ALL) — allogeneic
  • Hodgkin lymphoma — autologous
  • Non-Hodgkin lymphoma — autologous or allogeneic
  • Multiple myeloma — autologous
  • Aplastic anaemia — allogeneic
  • Thalassaemia major — allogeneic (curative)
  • Sickle cell disease — allogeneic

How Stem Cell Transplant Works (Step by Step)

  1. HLA typing and donor search
  2. Mobilisation (for autologous: G-CSF injections)
  3. Leukapheresis (stem cell collection)
  4. Conditioning regimen (myeloablative or reduced-intensity)
  5. Stem cell infusion (Day 0)
  6. Engraftment (Day +14 to +21)
  7. GVHD prophylaxis (for allogeneic)
  8. Long-term follow-up (immune reconstitution: 6–12 months)

Benefits of Stem Cell Transplant in India

  • Haploidentical transplant removes donor scarcity barrier
  • Large Indian bone marrow registry (DATRI) for unrelated donor search
  • Top Indian centres match Western OS and engraftment rates
  • Day 100 TRM at top centres: 5–10% for myeloablative, 3–5% for RIC

Best Hospitals for Stem Cell Transplant in India

  • AIIMS, New Delhi
  • Christian Medical College, Vellore
  • Tata Medical Center, Kolkata
  • Apollo Cancer Centre, Chennai
  • Narayana Hrudayalaya, Bangalore

Frequently Asked Questions

Q: What blood disorders can be cured with stem cell transplant in India?

A: Thalassaemia major has 80–90% cure rates with allogeneic HSCT from a matched sibling at India's top centres. Sickle cell disease achieves 85–90% event-free survival. Aplastic anaemia has 80–85% long-term survival with matched sibling HSCT.

Other Cancer Treatments in India